Emmaus Life Sciences, Inc. (EMMA) Fair Value 2026

EMMA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (33/100)

Quick Summary — As of 2026-08-27, Emmaus Life Sciences, Inc. (EMMA) trades at $0.05. QOC: 4.9/10. Value Trap Risk: 33/100 (LOW). 1/13 models active.

Key Facts

Ticker
EMMA
Price
$0.05
Quality Score
4.9/10
Value Trap Risk
33/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +111.6% upside with 41% confidence
Risk: Below-average Quality Score of 4.9/10 signals weak fundamentals

What Fair Value Does Each Model Give EMMA?

1 Intrinsic Value Models vs. Current Price ($0.05)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.11 +111.6%

All Models Active

All 1 models are displayed above.

What Is Emmaus Life Sciences, Inc. (EMMA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Emmaus Life Sciences, Inc.. Trading at $0.05 against an estimated intrinsic value of $0.11, 1 of 1 active models flag meaningful upside of +111.6% at the median.

What Do the Models Say About EMMA?

1 of 13 models are currently active for EMMA. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does EMMA Rank in Biotechnology?

Among 620 Biotechnology stocks, EMMA ranks #339 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Emmaus Life Sciences, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is EMMA a Value Trap?

CirclFi's Value Trap algorithm assigns EMMA a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Emmaus Life Sciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Emmaus Life Sciences, Inc. earns a quality score of 4.9/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every EMMA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across EMMA's 1 active models, average confidence is 41%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Emmaus Life Sciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ANROAlto Neuroscience, Inc.QOC 4.9OSRHOSR Health, Inc.QOC 4.9SRZNSurrozen, Inc.QOC 4.9LXEOLexeo Therapeutics, Inc.QOC 4.9CGEMCullinan Therapeutics, Inc.QOC 4.9AIMAIM ImmunoTech Inc.QOC 4.9DCOYDecoy Therapeutics Inc.QOC 4.3RPRXRoyalty Pharma plcQOC 8.1TRDAEntrada Therapeutics, Inc.QOC 5.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ANRO · OSRH · SRZN · LXEO · CGEM · AIM · DCOY · RPRX · TRDA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to EMMA?

6 companies across all industries closest to EMMA’s Quality of Company score of 4.9/10.

SEIISharing Economy International Inc.QOC 4.9CRSFCrisp Momentum Inc.QOC 4.9FRBTForbright, Inc.QOC 4.9LTCNGrayscale Litecoin TrustQOC 4.9LPLLG Display Co., Ltd.QOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SEII · CRSF · FRBT · LTCN · LPL · NVDA

Where Does EMMA Sit in CirclFi's Biotechnology Rankings?

EMMA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Emmaus Life Sciences, Inc.’s Valuation?

What is Emmaus Life Sciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Emmaus Life Sciences, Inc. (EMMA). The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is EMMA overvalued or undervalued right now?

At $0.05, 1 of 1 active models suggest EMMA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Emmaus Life Sciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.9 mean for EMMA?

Emmaus Life Sciences, Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on EMMA?

CirclFi analyzes EMMA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is EMMA a value trap in 2026?

Emmaus Life Sciences, Inc.'s Value Trap score is 33/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Emmaus Life Sciences, Inc. (EMMA) a Quality of Company score of 4.9/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/EMMA/ · Methodology
Primary sources for this EMMA valuation
  • Financial statements: Emmaus Life Sciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000822370) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for EMMA as of ; valuations recomputed .